Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,305 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05055791 | A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 312 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Sep 24, 2021 | clinicaltrials |
| NCT05054478 | Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation(PCL-2) | not yet recruiting | Phase 2 | 29 | Assistance Publique - Hôpitaux de ParisOTHER |
| 0 |
| Sep 23, 2021 |
| clinicaltrials |
| NCT04913103 | Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL(CLSGMCLPOLA) | not yet recruiting | Phase 2 | 21 | Czech Lymphoma Study GroupOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04856137 | A Phase I/II Study of Diffuse Large B-cell Lymphoma(DLBL) | not yet recruiting | Phase 1 / Phase 2 | 74 | National Health Research Institutes, TaiwanOTHER | 0 | Apr 23, 2021 | clinicaltrials |
| NCT04702932 | Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies(GEN-HEMO-INF) | not yet recruiting | — | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT04670055 | A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04541368 | A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04662788 | Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04657965 | LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies | not yet recruiting | Early Phase 1 | 144 | Zhejiang UniversityOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04658004 | NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04451200 | Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning(BUSEQ) | not yet recruiting | Phase 2 | 82 | Institut Paoli-CalmettesOTHER | 0 | Nov 17, 2020 | clinicaltrials |
| NCT04599543 | IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT04595162 | A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | not yet recruiting | Phase 1 | 12 | Peking University Third HospitalOTHER | 0 | Oct 20, 2020 | clinicaltrials |
| NCT04520529 | Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas(LYMPHOTEQ) | not yet recruiting | N/A | 500 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 20, 2020 | clinicaltrials |
| NCT04338386 | Detection and Pathogenesis of Novel Protein F | not yet recruiting | — | 100 | Wuhan Asia Heart HospitalOTHER | 0 | Apr 10, 2020 | clinicaltrials |
| NCT02497898 | Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma | not yet recruiting | Phase 2 | 1,000 | The First People's Hospital of ChangzhouOTHER | 0 | Jul 15, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Sep 24, 2021source: clinicaltrials